TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.19 by 9.57 percent. This is a 325 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $141.148 million which missed the analyst consensus estimate of $146.422 million by 3.60 percent. This is a 92.13 percent increase over sales of $73.466 million the same period last year.